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ThrombosisAbstract Gorham–Stout disease (GSD) is a rare osteolytic bone disease also known as vanishing
bone disease. The pathogenesis of GSD is not well understood. Studies showed that lymphatic and
blood endothelial cells in addition to macrophages secrete TNFa and IL-6 that stimulate osteoclast
formation with osteolysis. Also TNFa secretion inhibits osteoblast differentiation and new bone
formation. It is known that cytokines such as TNFa, IL-1 and complement system activation are
responsible for inflammation and necrosis in the vessel wall at vasculitis. Both diseases have similar
pathogenesis. Here, we presented a case of Gorham’s disease with involvement of bilateral humerus,
systemic arterial thrombosis and mesenteric vasculitis.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gorham–Stout disease (GSD) is a rare osteolytic bone disease
also known as vanishing bone disease. It is an musculoskeletal
disorder characterized by spontaneous and progressive osteol-
ysis, angiomatous proliferation and soft tissue swelling without
new bone formation, although first description of a humerus
osteolysis in 1838 by Jackson. Moreover, in 1955, Gorham
and Stout published a paper, which correlated the massive
osteolysis noted in the disease with hemangiomatosis.1 The
pathogenesis of GSD is not well understood. Studies showed
that lymphatic and blood endothelial cells in addition to
macrophages secrete TNFa, IL-1b and IL-6 that stimulate
osteoclast formation with osteolysis.2,3 Also TNFa secretedby macrophage and endothelial cells inhibits osteoblast differ-
entiation and new bone formation. Additionally, the signaling
pathway of the receptor of the lymphangiogenic growth factor
Platelet Derived Growth Factor BB(PDGFR-b) and vascular
endothelial growth factor (VEGF) family has the critical role
that could play in the pathogenetic mechanism of the dis-
ease.4,5 Besides the bone disease, also lymphatic vascular mal-
formations involving the skin and the soft tissues can be
adjacent to the diseased bone.4 It can affect any part of the
skeleton. The sites most affected are the cranium, shoulder
and pelvis.6 GSD shows no preference for gender or race
and occurs more often in children and young adults. Although
dissolution, fracture, fragmentation and disappearance of a
part of a bone are typical at X-ray diagnosis of GSD is based
on exclusion of other causes of osteolysis, such as infection,
cancer, inflammatory and endocrine disorders.7
Herein, we report a 50 years old female patient who had
been presented with osteolysis of bilateral humerus, systemic
thrombosis and mesenteric vasculitis..1016/j.
2 H.H. Yeter2. Case report
A 50 year-old woman was admitted to the hospital having
abdominal pain and anemia to find etiology of osteolysis of
humerus. Her shoulder pain had started five years earlier with
progressive loss of range of motion. She did not have any pre-
vious history of trauma but she was treated because of soft tis-
sue infection. There were no document neither tissue nor blood
culture positivity.
At the objective examination she presented with pain upon
palpation of bilateral shoulder. She also could not raise left
upper arm and right upper arm was limited to internal and
external rotation, abduction and adduction. At her abdominal
examination she had diffuse defence without rebound.
She underwent X-ray examination with the right and left
shoulder (Fig. 1). X-ray showed the right humerus radiolucent
foci (osteolytic lesions) and loss of tissue and left humerus
proximal resorption of bone. MRI on bilateral humerus
(Fig. 2) also showed complete bone resorption of left humerus
head and neck and scapula’s glenoid process and partial bone
resorption of right humerus. Bilateral shoulder muscles wide-
spread lipoid atrophy was seen. Her blood chemistry, parathy-
roid and thyroid hormone levels, serum immunoglobulins,
complement levels, and tumor markers were all normal
(Table 1). She had iron deficiency anemia and mild leukocyto-
sis. Sedimentation rate was high and also she had anti nuclear
anticor (ANA) positivity (1/320 titer). Lupus anticoagulants
and hereditary thrombophilia tests were negative except for
PAI heterozygosity (Table 2). Her Schirmer test was negative
and salivary gland biopsy was normal. Her upper and lower
endoscopy was normal except for gastritis.
Thorax CT showed thrombus in right subclavian artery and
aorta and third costa focal bone destruction with normal pul-
monary parenchyma. Abdominal CT angiography showed
thrombus in left common iliac artery, mesenteric vasculitis,
ileal wall thickness and partial intestinal obstruction. To
exclude hematologic malignancy bone marrow aspiration
and biopsy were performed. It was negative for malignancy
and dysplasia.Figure 1 Bilateral humerus X-ray. X-ray showed that right humer
humerus proximal resorption of bone.
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was reported nonspecific minimal chronic inflammatory pro-
cess. Tissue tuberculosis and aerobe culture were both
negative.
We started 1 mg/kg/day metilprednizolone as a treatment
of vasculitis. After one month follow-up she had no abdominal
pain and her acute phase reactants were normal. The second
month of discharge she admitted to emergency department
with acute abdominal pain and diffuse abdominal defence
and rebound. Her abdominal CT showed intestinal perfora-
tion. After surgery she died because of septic shock.
3. Discussion
GSD is a rare condition that is characterized by loss of bone
matrix, which is replaced by fibrotic tissue and proliferation
of vascular and lymphatic canals. There is no association
between GSD and vasculitis and thrombosis in the literature.
We can also not explain the bone findings of our patient with
vasculitis. Patient’s X-ray and MRI findings are appropriate
with GSD but lymphatic malformation and nonmalignant
hyperproliferation of small vessels have not seen in bone
biopsy taken from the patient. Presence of multiple thrombo-
sis, mesenteric vasculitis and ANA positivity was considered
systemic lupus erythematosus (SLE) but not enough to diag-
nose SLE to Systemic Lupus International collaborating clin-
ics classification criteria for systemic lupus erythematosus.8
In SLE, lupus vasculopathy is found in up to 40% patient
especially woman and typically characterized by inflammation
and necrosis in the vessel wall.9 It is known that cytokines such
as TNFa, IL-1 and complement system activation are respon-
sible for inflammation and necrosis in the vessel wall.10 Also
TNFa, IL-1b and IL-6 stimulate osteoclast formation with
osteolysis and the other way is TNFa inhibits osteoblast acti-
vation and new bone formation at GSD.2,3 Experimental ani-
mal models showed that, TNFa infusion was rapidly followed
by thrombin generation and the study with the colorectal can-
cer patients also showed association between TNFa levels and
venous thromboembolism risk.11 Chronic inflammation orus radiolucent foci(osteolytic lesions) and loss of tissue and left
on the basis of vasculopathy, Alex J Med (2016), http://dx.doi.org/10.1016/j.
Figure 2 Bilateral humerus MRI of patients. MRI showed complete bone resorption of left humerus head and neck and scapula’s
glenoid process and partial bone resorption of right humerus. Bilateral shoulder muscles widespread lipoid atrophy was seen.
Table 1 Laboratory tests.
Results Normal range
ALTa 7 l/L <33
ASTa 13 l/L <31
GGTa 24 l/L <36
ALPa 76 l/L <104
T. Bilirubin 0.4 mg/dl 0.1–1.2
Albumina 3.24 g/dl 3.4–4.8
Creatinine 0.52 mg/dl 0.5–0.9
CKa 141 l/L 26–192
LDHa 175 l/L 240–480
TSHa 1.7 lIU/L 0.27–4.2
Hemoglobin 10.4 g/dl 11.7–15.5
MCVa 89.7 fl 80–95
Leukocyte 14  103 lL 4–11.2  103
Neutrophil 12.9  103 lL 1.8–6.4  103
Thrombocyte 352  103 lL 159–388  103
Sedimentation 66 mm/h 0–25
Ca 125a 4.5 0–35 U/ml
Ca 19-9a 32.5 0–35 U/ml
Ca 15-3a 6.1 0–31.3 U/ml
CEAa 1.37 0–3 ng/mL
a ALT: Alanine transaminase; AST: Aspartate aminotransferase;
GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase;
CK: Creatine kinase; LDH: Lactate dehydrogenase; TSH: Thyroid
stimulating hormone; MCV: Mean corpuscular volume; Ca: car-
bohydrate antigen; CEA: Carcinoembryonic antigen.
Table 2 Immunologic tests.
Results Normal range
C-rpa 2.18 0–1 mg/dl
ANAa 1/320 Negative
Anti ds-DNA Negative Negative
ENA-SsAa Positive Negative
ENA-SsB Negative Negative
ENA-Jo1 Negative Negative
ENA-Scl70 Negative Negative
Anti phospholipid IgM Negative Negative
Anti phospholipid IgG Negative Negative
Beta-2 glycoprotein IgM Negative Negative
Beta-2 glycoprotein IgG Negative Negative
Anti cardiolipin Antibody IgM Negative Negative
Anti cardiolipin Antibody IgG Negative Negative
ANCA profilea Negative Negative
Anti HBc total Negative Negative
Anti HBs 14n IU/ml 0–10
Anti HCV Negative Negative
TPHAa Negative Negative
Brucella agglutination Negative Negative
C3a 128 mg/dl 79–152
C4a 25 mg/dl 16–38
IgA 361 82–453 mg/dl
IgG 1170 751–1560 mg/dl
IgM 64 46–304 mg/dl
a CRP: C-reactive protein; RF: Rheumatoid factor; ANA: Anti
nuclear anticor; C3: Complement 3; C4: Complement 4; ENA:
extractable nuclear antigens; ANCA: antineutrophil cytoplasmic
antibodies; TPHA: Treponema pallidum hemagglutination assay.
Gorham–Stout disease 3autoinflammatory diseases are also possible cause of
thrombosis.12
In a study conducted by Franchi et al. to find a diagnostic
marker for GSD, CD105 expression was found to be signifi-
cantly higher in GSD vessels compared to control group.13
Similarly, CD105 (endoglin) expression was significantlyPlease cite this article in press as: Yeter HH Gorham–Stout disease or new entity
ajme.2016.03.006higher in systemic vasculitis and the expression of it correlates
with disease activity.14–16on the basis of vasculopathy, Alex J Med (2016), http://dx.doi.org/10.1016/j.
4 H.H. YeterAs a major molecule in angiogenesis, VEGF also con-
tributes to the regulation of the immune system.17 Significantly
increased levels of VEGF were demonstrated in activation of
vasculitis as well as in GSD.2,3,18
4. Conclusion
TNFa, IL-1b, IL-6, VEGF and CD105 have pathophysiolog-
ical role both in the vasculitis and in the GSD. This common
pathway increases the risk of coexistence of both diseases.
Thrombosis may be the result of direct effect of cytokines such
as TNFa or chronic inflammation or autoinflammation. To
our knowledge this report is the first combination of GSD,
arterial thrombosis and vasculitis in the literature. Perhaps it
is a new entity on the basis of vasculopathy including vasculi-
tis, thrombosis and GSD like disease.
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